You are here

Home

Clinical Trials: Cord Blood

Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
Condition:   Infusion Reactions
Intervention:   Biological: unlicensed CBU
Sponsor:   New York Blood Center
Recruiting - verified April 2017
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting
Donor Cord Blood T-Cell Infusion After Stem Cell Transplant in Treating Patients With Relapsed Hematological Malignancies
Condition:   Hematopoietic and Lymphoid Cell Neoplasm
Interventions:   Biological: Aldesleukin;   Procedure: Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion;   Biological: Umbilical Cord Blood-Derived Lymphocyte Therapy
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Terminated
Autologous Cord Blood Stem Cells for Autism
Condition:   Autism
Interventions:   Biological: Autologous Cord Blood Stem Cells;   Biological: Placebo
Sponsor:   Sutter Health
Completed - verified May 2017
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
Conditions:   Lysosomal Storage Disease;   Peroxisomal Disorder
Interventions:   Drug: Campath-1H;   Drug: Clofarabine;   Drug: Melphalan;   Radiation: Total Body Irradiation with Marrow Boosting;   Biological: Hematopoietic stem cell transplantation;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil
Sponsor:   Masonic Cancer Center, University of Minnesota
Completed
The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.
Condition:   Hematologic Malignancies
Interventions:   Biological: ProHema-CB;   Biological: Untreated CB
Sponsor:   Fate Therapeutics
Terminated - verified June 2017
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect
Conditions:   Degenerative Osteoarthritis;   Defect of Articular Cartilage
Interventions:   Biological: CARTISTEM;   Procedure: Microfracture
Sponsors:   Medipost Co Ltd.;   Dong-A Pharmaceutical Co., Ltd.
Completed - verified April 2017
Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies
Condition:   Hematologic Malignancies
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Radiation: Total Body Irradiation;   Biological: Umbilical Cord Blood
Sponsor:   University of Virginia
Terminated
NK Cells in Cord Blood Transplantation
Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   DS Stage II Plasma Cell Myeloma;   DS Stage III Plasma Cell Myeloma;   High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements;   ISS Stage II Plasma Cell Myeloma;   ISS Stage III Plasma Cell Myeloma;   Myelodysplastic Syndrome;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Small Lymphocytic Lymphoma;   Secondary Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome
Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Biological: Natural Killer Cell Therapy;   Biological: Rituximab;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting
Human Placental-Derived Stem Cell Transplantation
Conditions:   Mucopolysaccharidosis I;   Mucopolysaccharidosis VI;   Adrenoleukodystrophy;   Niemann-Pick Disease;   Metachromatic Leukodystrophy;   Wolman Disease;   Krabbe's Disease;   Gaucher's Disease;   Fucosidosis;   Batten Disease;   Severe Aplastic Anemia;   Diamond-Blackfan Anemia;   Amegakaryocytic Thrombocytopenia;   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia
Intervention:   Drug: Human Placental Derived Stem Cell
Sponsor:   New York Medical College
Active, not recruiting

Pages